Page 403 - Williams Hematology ( PDFDrive )

378 Part V: Therapeutic Principles Chapter 23: Hematopoietic Cell Transplantation 379

217. Horan JT, Logan BR, Agovi-Johnson MA, et al: Reducing the risk for transplanta- 244. Farag SS, Maharry K, Zhang MJ, et al: Comparison of reduced-intensity hematopoietic
tion-related mortality after allogeneic hematopoietic cell transplantation: How much cell transplantation with chemotherapy in patients age 60–70 years with acute myelog-
progress has been made? J Clin Oncol 29:805–813, 2011. enous leukemia in first remission. Biol Blood Marrow Transplant 17:1796–1803, 2011.
218. Gooley TA, Chien JW, Pergam SA, et al: Reduced mortality after allogeneic hematopoi- 245. Kurosawa S, Yamaguchi T, Uchida N, et al: Comparison of allogeneic hematopoietic cell
etic-cell transplantation. N Engl J Med 363:2091–2101, 2010. transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous
219. Hamadeh R, Ardehali A, Locksley RM, et al: Fatal aspergillosis associated with smoking leukemia in first complete remission. Biol Blood Marrow Transplant 17:401–411, 2011.
contaminated marijuana, in a marrow transplant recipient. Chest 94:432–433, 1988. 246. Schlenk RF, Dohner K, Krauter J, et al: Mutations and treatment outcome in cytogenet-
220. Szyper-Kravitz M, Lang R, Manor Y, et al: Early invasive pulmonary aspergillosis in a ically normal acute myeloid leukemia. N Engl J Med 358:1909–1918, 2008.
leukemia patient linked to aspergillus contaminated marijuana smoking. Leuk Lym- 247. Cornelissen JJ, Gratwohl A, Schlenk RF, et al: The European LeukemiaNet AML Work-
phoma 42:1433–1437, 2001. ing Party consensus statement on allogeneic HSCT for patients with AML in remission:
221. Ladenstein R, Potschger U, Hartman O, et al: 28 years of high-dose therapy and SCT An integrated-risk adapted approach. Nat Rev Clin Oncol 9:579–590, 2012.
for neuroblastoma in Europe: Lessons from more than 4000 procedures. Bone Marrow 248. Appelbaum FR: Indications for allogeneic hematopoietic cell transplantation for acute
Transplant 41 (Suppl 2):S118–S127, 2008. myeloid leukemia in the genomic era. Am Soc Clin Oncol Educ Book e327–e333, 2014.
222. Yalcin B, Kremer LC, Caron HN, et al: High-dose chemotherapy and autologous hae- 249. Yeshurun M, Labopin M, Blaise D, et al: Impact of postremission consolidation che-
matopoietic stem cell rescue for children with high-risk neuroblastoma. Cochrane motherapy on outcome after reduced-intensity conditioning allogeneic stem cell trans-
Database Syst Rev 8:Cd006301, 2013. plantation for patients with acute myeloid leukemia in first complete remission: A
223. Matthay KK, Reynolds CP, Seeger RC, et al: Long-term results for children with high- report from the Acute Leukemia Working Party of the European Group for Blood and
risk neuroblastoma treated on a randomized trial of myeloablative therapy followed Marrow Transplantation. Cancer 120:855–863, 2014.
by 13-cis-retinoic acid: A children’s oncology group study. J Clin Oncol 27:1007–1013, 250. Warlick ED, Paulson K, Brazauskas R, et al: Effect of postremission therapy before
2009. reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia
224. Lazarus HM, Stiff PJ, Carreras J, et al: Utility of single versus tandem autotransplants in first complete remission. Biol Blood Marrow Transplant 20:202–208, 2014.
for advanced testes/germ cell cancer: A Center for International Blood and Marrow 251. Armistead PM, de Lima M, Pierce S, et al: Quantifying the survival benefit for alloge-
Transplant Research (CIBMTR) analysis. Biol Blood Marrow Transplant 13:778–789, neic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia.
2007. Biol Blood Marrow Transplant 15:1431–1438, 2009.
225. Howard DH, Kenline C, Lazarus HM, et al: Abandonment of high-dose chemotherapy/ 252. Kroger N, Brand R, van Biezen A, et al: Autologous stem cell transplantation for ther-
hematopoietic cell transplants for breast cancer following negative trial results. Health apy-related acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow
Serv Res 46:1762–1777, 2011. Transplant 37:183–189, 2006.
226. Berry DA, Ueno NT, Johnson MM, et al: High-dose chemotherapy with autologous 253. Laughlin MJ, Eapen M, Rubinstein P, et al: Outcomes after transplantation of cord
stem-cell support as adjuvant therapy in breast cancer: Overview of 15 randomized blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med
trials. J Clin Oncol 29:3214–3223, 2011. 351:2265–2275, 2004.
227. Kahl C, Leisenring W, Deeg HJ, et al: Cyclophosphamide and antithymocyte globulin as 254. Rocha V, Labopin M, Sanz G, et al: Transplants of umbilical-cord blood or bone mar-
a conditioning regimen for allogeneic marrow transplantation in patients with aplastic row from unrelated donors in adults with acute leukemia. N Engl J Med 351:2276–2285,
anaemia: A long-term follow-up. Br J Haematol 130:747–751, 2005. 2004.
228. Burroughs LM, Woolfrey AE, Storer BE, et al: Success of allogeneic marrow transplan- 255. Fung HC, Stein A, Slovak M, et al: A long-term follow-up report on allogeneic stem
tation for children with severe aplastic anaemia. Br J Haematol 158:120–128, 2012. cell transplantation for patients with primary refractory acute myelogenous leukemia:
229. Gaziev J, Marziali M, Isgro A, et al: Bone marrow transplantation for thalassemia from Impact of cytogenetic characteristics on transplantation outcome. Biol Blood Marrow
alternative related donors: Improved outcomes with a new approach. Blood 122:2751– Transplant 9:766–771, 2003.
2756, 2013. 256. Pui CH, Evans WE: Treatment of acute lymphoblastic leukemia. N Engl J Med 354:166–
230. La Nasa G, Caocci G, Efficace F, et al: Long-term health-related quality of life evaluated 178, 2006.
more than 20 years after hematopoietic stem cell transplantation for thalassemia. Blood 257. Cornelissen JJ, van der Holt B, Verhoef GE, et al: Myeloablative allogeneic versus autol-
122:2262–2270, 2013. ogous stem cell transplantation in adult patients with acute lymphoblastic leukemia
231. Lucarelli G, Isgro A, Sodani P, et al: Hematopoietic SCT for the Black African and in first remission: A prospective sibling donor versus no-donor comparison. Blood
non-Black African variants of sickle cell anemia. Bone Marrow Transplant 49: 113:1375–1382, 2009.
1376–1381, 2014. 258. Goldstone AH, Richards SM, Lazarus HM, et al: In adults with standard-risk acute lym-
232. Hsieh MM, Fitzhugh CD, Weitzel RP, et al: Nonmyeloablative HLA-matched sibling phoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic
allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. transplantation in first complete remission, and an autologous transplantation is less
JAMA 312:48–56, 2014. effective than conventional consolidation/maintenance chemotherapy in all patients:
233. Angelucci E, Matthes-Martin S, Baronciani D, et al: Hematopoietic stem cell transplan- Final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood
tation in thalassemia major and sickle cell disease: Indications and management recom- 111:1827–1833, 2008.
mendations from an international expert panel. Haematologica 99:811–820, 2014. 259. Gupta V, Richards S, Rowe J: Allogeneic, but not autologous, hematopoietic cell trans-
234. Romero Z, Urbinati F, Geiger S, et al: Beta-globin gene transfer to human bone marrow plantation improves survival only among younger adults with acute lymphoblastic leu-
for sickle cell disease. J Clin Invest 2013. [Epub ahead of print] kemia in first remission: An individual patient data meta-analysis. Blood 121:339–350,
235. Pai SY, Logan BR, Griffith LM, et al: Transplantation outcomes for severe combined 2013.
immunodeficiency, 2000–2009. N Engl J Med 371:434–446, 2014. 260. Pidala J, Djulbegovic B, Anasetti C, et al: Allogeneic hematopoietic cell transplantation
236. Moratto D, Giliani S, Bonfim C, et al: Long-term outcome and lineage-specific chi- for adult acute lymphoblastic leukemia (ALL) in first complete remission. Cochrane
merism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell Database Syst Rev 10:Cd008818, 2011.
transplantation in the period 1980–2009: An international collaborative study. Blood 261. Ram R, Storb R, Sandmaier BM, et al: Non-myeloablative conditioning with allogeneic
118:1675–1684, 2011. hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic
237. Boelens JJ, Aldenhoven M, Purtill D, et al: Outcomes of transplantation using various leukemia. Haematologica 96:1113–1120, 2011.
hematopoietic cell sources in children with Hurler syndrome after myeloablative con- 262. Laport GG, Alvarnas JC, Palmer JM, et al: Long-term remission of Philadelphia chro-
ditioning. Blood 121:3981–3987, 2013. mosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell
238. Cornelissen JJ, van Putten WL, Verdonck LF, et al: Results of a HOVON/SAKK donor transplantation from matched sibling donors: A 20-year experience with the fraction-
versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplanta- ated total body irradiation-etoposide regimen. Blood 112:903–909, 2008.
tion in first remission acute myeloid leukemia in young and middle-aged adults: Bene- 263. Mizuta S, Matsuo K, Nishiwaki S, et al: Pretransplant administration of imatinib for
fits for whom? Blood 109:3658–3666, 2007. allo-HSCT in patients with BCR-ABL-positive acute lymphoblastic leukemia. Blood
239. Suciu S, Mandelli F, de Witte T, et al: Allogeneic compared with autologous stem cell 123:2325–2332, 2014.
transplantation in the treatment of patients younger than 46 years with acute myeloid 264. Schultz KR, Carroll A, Heerema NA, et al: Long-term follow-up of imatinib in pediatric
leukemia (AML) in first complete remission (CR1): An intention-to-treat analysis of Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology
the EORTC/GIMEMAAML-10 trial. Blood 102:1232–1240, 2003. Group study AALL0031. Leukemia 28:1467–1471, 2014.
240. Koreth J, Schlenk R, Kopecky KJ, et al: Allogeneic stem cell transplantation for acute 265. Attal M, Harousseau JL, Stoppa AM, et al: A prospective, randomized trial of autol-
myeloid leukemia in first complete remission: Systematic review and meta-analysis of ogous bone marrow transplantation and chemotherapy in multiple myeloma. Inter-
prospective clinical trials. JAMA 301:2349–2361, 2009. groupe Francais du Myelome. N Engl J Med 335:91–97, 1996.
241. Yanada M, Matsuo K, Emi N, et al: Efficacy of allogeneic hematopoietic stem cell 266. Child JA, Morgan GJ, Davies FE, et al: High-dose chemotherapy with hematopoietic
transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease stem-cell rescue for multiple myeloma. N Engl J Med 348:1875–1883, 2003.
remission: A metaanalysis. Cancer 103:1652–1658, 2005. 267. Fermand JP, Katsahian S, Divine M, et al: High-dose therapy and autologous blood
242. Walter RB, Pagel JM, Gooley TA, et al: Comparison of matched unrelated and matched stem-cell transplantation compared with conventional treatment in myeloma patients
related donor myeloablative hematopoietic cell transplantation for adults with acute aged 55 to 65 years: Long-term results of a randomized control trial from the Group
myeloid leukemia in first remission. Leukemia 24:1276–1282, 2010. Myelome-Autogreffe. J Clin Oncol 23:9227–9233, 2005.
243. Saber W, Opie S, Rizzo JD, et al: Outcomes after matched unrelated donor versus iden- 268. Fermand JP, Ravaud P, Chevret S, et al: High-dose therapy and autologous peripheral
tical sibling hematopoietic cell transplantation in adults with acute myelogenous leuke- blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment?
mia. Blood 119:3908–3916, 2012. Results of a multicenter sequential randomized clinical trial. Blood 92:3131–3136, 1998.

Kaushansky_chapter 23_p0353-0382.indd 378 9/19/15 12:47 AM